Is infliximab included in medical insurance?

Infliximab (Infliximab), as an anti-tumor necrosis factor α (TNF-α) monoclonal antibody widely used around the world, has achieved significant efficacy in the treatment of a variety of autoimmune diseases. With the continuous improvement of my country's medical system and the promotion of the application of biological agents, infliximab has been launched domestically in recent years and has been included in the national medical insurance directory, bringing more economical and affordable treatment options to the majority of patients.

Specifically, the launch of infliximab has greatly enriched the drug structure for the treatment of immune-related diseases in my country. It is widely used in Crohn's disease (CD), ulcerative colitis, rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis and other diseases. By specifically neutralizing TNF-α, the drug effectively inhibits the inflammatory cascade, reduces inflammatory symptoms, and improves patients' quality of life. Its inclusion in medical insurance marks the country's recognition of biological agents, and also reflects the support of medical insurance policies for high-priced innovative drugs.

The price of infliximab in the medical insurance directory varies according to different versions. The price of imported original research drugs is relatively high, and the cost of a single treatment may range from several thousand yuan to tens of thousands of yuan, which is mainly affected by production costs, tariffs and circulation links. With the rise of domestic biosimilar drugs, market competition has intensified and prices have become more affordable. The domestic version is usually in the range of several thousand yuan, which greatly reduces the financial burden on patients and allows more moderate to severe patients to receive standard treatment.

Medical insurance coverage allows patients to significantly reduce their expenditure on treatment, especially during long-term maintenance treatment, which reduces the financial pressure of continued medication. At the same time, the inclusion of medical insurance also promotes the rational use and standardized management of infliximab by medical staff, and promotes the optimization of clinical pathways. In the future, with the advent of more biosimilars and new biologics, medical insurance policies may be further improved, and patient access to medication will continue to improve.

Reference materials:https://www.drugs.com/infliximab.html